In the wake of COVID-19, government officials around the world face unprecedented decisions about when and to what extent they should reopen their respective societies before effective anti-viral medications or vaccines have been developed, necessary regulatory approvals obtained, and those solutions are manufactured for public use. Fundamentally, such decisions will require a delicate balance between protecting public health and facilitating economic growth, which, as we have all been reminded this year, are deeply intertwined.
Recent Posts
- Despite Tweaks, PREVAIL 2025 Would Still Transform the PTAB
- Patent Eligibility Reform Returns to the Hill: PERA 2025 Explained
- PayPal, Apple Succeed in Scrapping Fintiv’s Patent Claims at CAFC
- CAFC Affirms TTAB’s Genericness Test for Color Marks
- AI and the Law: How Companies Can Navigate IP Risk and Seize Opportunity | IPWatchdog Unleashed